Back to User profile » Dr Fabrizio Cantini
Papers published by Dr Fabrizio Cantini:
Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data
Benucci M, Damiani A, Li Gobbi F, Grossi V, Infantino M, Manfredi M, Niccoli L, Cantini F
Therapeutics and Clinical Risk Management 2020, 16:287-297
Published Date: 16 April 2020
Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting
Degli Esposti L, Perrone V, Sangiorgi D, Alessandrini D, Buda S, Cantini F, Mazzini E, Toma C, De Solda F
Patient Preference and Adherence 2019, 13:187-194
Published Date: 22 January 2019
Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
Niccoli L, Nannini C, Blandizzi C, Mantarro S, Mosca M, Di Munno O, Goletti D, Benucci M, Li Gobbi F, Cassarà E, Kaloudi O, Cantini F
Therapeutics and Clinical Risk Management 2018, 14:2097-2111
Published Date: 24 October 2018
Focus on biosimilar etanercept – bioequivalence and interchangeability
Cantini F, Benucci M
Biologics: Targets and Therapy 2018, 12:87-95
Published Date: 30 August 2018
Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study
Cantini F, Niccoli L, Cassara E, Kaloudi O, Nannini C
Biologics: Targets and Therapy 2013, 7:1-6
Published Date: 4 January 2013
Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study
Cantini F, Niccoli L, Cassarà E, Kaloudi O, Nannini C
Biologics: Targets and Therapy 2012, 6:201-206
Published Date: 12 July 2012
Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients
Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E, Susini M, Lenzetti I
Biologics: Targets and Therapy 2012, 6:5-12
Published Date: 29 December 2011